NASDAQ, MNOV - Medicinova Inc
We are a biopharmaceutical company focused on acquiring and developing novel,
small molecule therapeutics for the treatment of diseases with unmet medical
need with a specific focus on the U.S. market. Through strategic alliances
primarily with Japanese pharmaceutical companies, we are developing a
diversified portfolio of clinical and preclinical product candidates, each of
which we believe has a well-characterized and differentiated therapeutic
profile, attractive commercial potential and patent assets having claims of
commercially adequate scope.
To date, we have acquired licenses to eight compounds for the development of ten
product candidates in what we believe are large and underserved markets. ...
Read SEC Filing on NASDAQ.com »